WSTAM
FENC icon

Wilbanks Smith & Thomas Asset Management’s Fennec Pharmaceuticals FENC Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-100
Closed -$1K – 676
2018
Q3 		$1K Buy
+100
New +$928 ﹤0.01% 1512

Other funds holding FENC

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's FENC Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of Fennec Pharmaceuticals (FENC) in Q4 2018, closing a stake of 100 shares — an estimated $1K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in FENC in Q3 2018 and held it in 1 quarter. The position peaked at $1K in Q3 2018. 47 funds tracked by Wall St. Rank hold FENC as of Q4 2018.

  • Wilbanks Smith & Thomas Asset Management reported no remaining Fennec Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 100 Fennec Pharmaceuticals shares in Q4 2018, an estimated $1K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in Fennec Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • Wilbanks Smith & Thomas Asset Management's Fennec Pharmaceuticals position peaked at $1K in Q3 2018.
  • 47 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.